NEW YORK (Reuters Health) - The use of androgen deprivation therapy appears to increase the risk of death from cardiovascular disease among men who undergo radical prostatectomy for localized prostate cancer, new research shows.Androgen deprivation therapy is a type of hormone therapy, usually given to men with advanced or difficult to treat cancers. It blocks the production of another male sex hormone, testosterone, which drives tumor growth.
